Novo Nordisk suspended from leading UK trade group over obesity marketing 'breach'
Novo Nordisk was slapped with a two-year suspension from the UK pharma industry group, the Association of the British Pharmaceutical Industry (ABPI), on Thursday for crossing the line on its code of conduct.
The suspension stems from an investigation by the Prescription Medicines Code of Practice Authority (PMCPA), which oversees the complaints procedure of the ABPI Code, over a LinkedIn post promoting a “free weight management course” by a third-party provider that was supported by Novo Nordisk.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,900+ biopharma pros reading Endpoints daily — and it's free.